SCHEMBL6874445

SCHEMBL6874445

Cc1nc(C)c(Cl)c(NCc2cc(OCC(F)(F)F)c(OCc3ccccc3)c(Br)n2)n1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 5/20 0.34
METAP2 P50579 2/20 0.34
MAPT P10636 5/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
GAA P10253 3/20 0.33
TP53 P04637 2/20 0.33
THRB P10828 2/20 0.33
P2RX7 Q99572 2/20 0.33
LMNA P02545 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GCK P35557 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HTT P42858 3/20 0.32
KDM4E B2RXH2 1/20 0.32
BLM P54132 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
STAT3 P40763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6884677 0.81 METAP1 (0.31) METAP1
SCHEMBL6740329 0.81 KMT2A (0.46) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL6883265 0.78 THRA (0.36) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL6741858 0.74 KMT2A (0.59) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL6882105 0.74 GCK (0.41) METAP1METAP2MAPTMEN1KMT2A
SCHEMBL7046783 0.73 DGAT2 (0.32)
SCHEMBL6742507 0.71 MAPT (0.36) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL6876869 0.71 METAP1 (0.43) METAP1METAP2LMNAHTT
SCHEMBL6740580 0.71 BCHE (0.51) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL15685008 0.70 F2 (0.51) MAPTMEN1KMT2AGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040158066-A1 Novel pyridylmethylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-12 US disclosed
EP-1395592-A1 NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES ALTANA Pharma AG (DE) 2004-03-10 EP disclosed
WO-2002094831-A1 NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158066-A1 Novel pyridylmethylaminopyrimidines PGLS, PLPBP, PDXK METAP1 680/4885METAP2 759/4885MAPT 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.